Ionis Pharmaceuticals upgraded to Overweight from Equal Weight at Barclays
Barclays upgraded Ionis Pharmaceuticals (IONS) to Overweight from Equal Weight with a price target of $57, up from $51, ahead of Tryngolza Phase 3 CORE/CORE2 data in severe hypertriglyceridemia due likely in September. After having spoken with three …